AUPH - Aurinia Pharmaceuticals guides Q4 revenue above estimates

• Aurinia Pharmaceuticals ( NASDAQ: AUPH ) has reported prelim net revenue of ~$28.4M for fourth quarter compared to consensus estimate of $27.13M.
• For the three months ended Dec. 31, 2022, preliminary unaudited net revenues included net product revenues of ~$28.3M and license and collaboration revenue of ~$0.1M.
• Lupkynis, the firm's FDA-approved oral therapy for lupus nephritis, showed substantial growth, including an increased total number of patients on therapy and an uptick in patient start forms in the back half of the fourth quarter, compared to the monthly average in the third quarter of 2022.
• Full year 2022 net revenue were $134M vs. $132.84M consensus, with net product revenue coming in at $103.5M.
• As of Dec. 31, 2022, the company had unaudited cash, cash equivalents and restricted cash and investments of ~$388.7M.
• The company reiterated its net product revenue guidance of $120M-$140M for 2023.

For further details see: